Why the study?
Does maternal administration of acebutolol compared to methyldopa affect neonatal systolic blood pressure, heart rate, and blood glucose in infants born to mothers with hypertension in pregnancy?
Does maternal administration of acebutolol compared to methyldopa affect neonatal systolic blood pressure, heart rate, and blood glucose in infants born to mothers with hypertension in pregnancy?
Maternal administration of acebutolol for hypertension in pregnancy is associated with significantly lower neonatal blood pressure and heart rate in the first three days of life compared to methyldopa.
Neonates of mothers given acebutolol may warrant BP monitoring; this cohort study leaves open effects on treatment choice in hypertensive pregnancy.
Systolic blood pressure, heart rate, and blood glucose concentration were measured in the first three days of life in 10 infants born to mothers who had received acebutolol, a cardioselective beta-adrenergic-blocking agent, for hypertension in pregnancy and compared with values in 10 infants whose mothers had received methyldopa. The blood pressure was expressed as a percentage of the expected value. Blood pressure was significantly lower in the infants of the mothers given acebutolol (p less than 0.02, less than 0.01, and less than 0.01 respectively during the three days of observation). Heart rate was also lower, but the significance was only at the 0.05 level. Blood glucose was not significantly different between the two groups. These results suggest that care should be taken in prescribing beta-adrenergic-blocking drugs during pregnancy.
No takes yet. Share an insight, caveat, or question.
Dumez et al. (1981) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: